Savient Pharmaceuticals Inc unveils Named Patient Programme for KRYSTEXXA for RCG patients in the EU.
M2 PHARMA-March 6, 2012-Savient Pharmaceuticals Inc unveils Named Patient Programme for KRYSTEXXA for RCG patients in the EU(C)2012 M2 COMMUNICATIONS
Biopharmaceutical company Savient Pharmaceuticals Inc (NASDAQ:SVNT) reported on Monday the launch of KRYSTEXXA in the EU to healthcare professionals and their patients suffering from refractory chronic gout (RCG) through a Named Patient Programme.
This Named Patient Programme is sponsored by the company's wholly-owned subsidiary, Savient Pharma Ireland Limited, and managed by Idis Limited.
The company added that RCG is a difficult-to-treat form of gout and currently there are no other available therapies approved in the EU for the treatment of RCG.
Under a Named Patient Programme, treatments that are pending approval by the European Medicines Agency (EMA) can be legally administered to patients who are suffering from serious diseases until they are commercially available in each market.
According to Savient, it is seeking approval for KRYSTEXXA in Europe and filed its regulatory application with the EMA in May 2011. KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme for administration by intravenous infusion for the treatment of refractory chronic gout (RCG) in adult patients.
((Comments on this story may be sent to firstname.lastname@example.org)).END.PUB430>PDMarch 6, 2012>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 6, 2012|
|Previous Article:||Vermillion Inc awarded US Notice of Allowance for new angiogenic biomarkers patent.|
|Next Article:||ACADIA Pharmaceuticals extends drug discovery partnership with Allergan Inc.|